George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick pickspolarean Regulatory News (POLX)

Share Price Information for polarean (POLX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.30
Bid: 4.20
Ask: 4.40
Change: 0.00 (0.00%)
Spread: 0.20 (4.762%)
Open: 4.30
High: 4.30
Low: 4.30
Prev. Close: 4.30
POLX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

13 Jan 2020 07:00

RNS Number : 5145Z
Polarean Imaging PLC
13 January 2020
 

13 January 2020

 

Polarean Imaging Plc

("Polarean" or the "Company")

 

Holding(s) in Company

 

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary magnetic resonance imaging (MRI) drug-device combination, received notification on 10 January 2020 that Tyndall Investment Management now holds 4,917,016 ordinary shares of £0.00037 in Polarean, which represents 4.3% of the Company's issued share capital, with voting rights.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

Enquiries:

 

Polarean Imaging plc

www.polarean.com / www.polarean-ir.com

Richard Hullihen, Chief Executive Officer

Via Walbrook PR

Richard Morgan, Chairman

SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

David Hignell, Soltan Tagiev (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

Walbrook PR

Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com

Paul McManus / Anna Dunphy

 

Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001

 

 

About Polarean (www.polarean.com)

 

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution medical imaging market.

 

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

 

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate and less harmful to the patient than current methods. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.

 

The Group also develops and manufactures high performance MRI radiofrequency (RF) coils which are a required component for imaging 129Xe in the MRI system. The development of these coils by the Group facilitates the adoption of the Xenon technology by providing application-specific RF coils which optimise the imaging of 129Xe in MRI equipment for use as a medical diagnostic as well as a method of monitoring the efficacy of therapeutic intervention.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLUUSBRRWUAAAR
Date   Source Headline
14th Mar 20247:00 amRNSExercise of Warrants, Issue of Equity and TVR
12th Mar 20243:59 pmRNSHolding(s) in Company
29th Feb 20247:00 amRNS2024 Polarean Strategy Update
26th Jan 20247:00 amRNSBlock Listing Six Monthly Return
15th Jan 20247:00 amRNSComment re: share purchase
12th Jan 20245:00 pmRNSHolding(s) in Company
12th Jan 20245:00 pmRNSHolding(s) in Company
7th Dec 20237:00 amRNSCompany Update
27th Nov 20237:00 amRNSHolding(s) in Company
27th Sep 20231:59 pmRNSDirectorate Change
8th Sep 20237:00 amRNSPartnership with VIDA
7th Sep 20234:54 pmRNSHalf-year Report
7th Sep 20237:00 amRNSHalf-year Report
5th Sep 202311:51 amRNSReimbursement code price range for XENOVIEW
29th Aug 20237:00 amRNSCMS grants reimbursement code for XENOVIEW
21st Aug 20235:29 pmRNSHolding(s) in Company
15th Aug 20237:00 amRNSNotice of Results
7th Aug 20237:00 amRNSExercise of Warrants
3rd Aug 20237:00 amRNSClearance received for new MRI chest coil
31st Jul 20237:00 amRNSClinical imaging with XENOVIEW in Missouri
27th Jul 20237:00 amRNSBlock Listing Six Monthly Return
30th Jun 20237:00 amRNSExercise of Warrants
28th Jun 20233:00 pmRNSResult of AGM
21st Jun 20237:00 amRNSAppointment of Dr. Christopher von Jako as new CEO
2nd Jun 20233:00 pmRNSCollaboration with Philips at ISMRM 2023
2nd Jun 20237:00 amRNSExtension of Warrants
26th May 20237:00 amRNSFinal Results
11th May 20232:42 pmRNSFirst clinical scan using XENOVIEW in Cincinnati
3rd May 20235:00 pmRNSFeatured at 2023 ATS Respiratory Innovation Summit
26th Apr 20237:00 amRNSFirst order for XENOVIEW gas blend received
17th Apr 20237:00 amRNSAppointment of Dan Brague as consultant
14th Mar 20237:30 amRNSRestoration - Polarean Imaging PLC
14th Mar 20237:00 amRNSRequest for temporary suspension to be lifted
13th Mar 20237:30 amRNSSuspension - Polarean Imaging PLC
13th Mar 20237:00 amRNSSilicon Valley Bank Relationship
20th Feb 20234:35 pmRNSPrice Monitoring Extension
15th Feb 20237:00 amRNSInvestor presentation
13th Feb 20232:05 pmRNSSecond Price Monitoring Extn
13th Feb 20232:00 pmRNSPrice Monitoring Extension
13th Feb 202311:05 amRNSSecond Price Monitoring Extn
13th Feb 202311:00 amRNSPrice Monitoring Extension
13th Feb 20239:05 amRNSSecond Price Monitoring Extn
13th Feb 20239:00 amRNSPrice Monitoring Extension
13th Feb 20237:00 amRNSCompany Update
1st Feb 20234:40 pmRNSSecond Price Monitoring Extn
1st Feb 20234:35 pmRNSPrice Monitoring Extension
1st Feb 20234:25 pmRNSFDA grants New Chemical Entity designation
27th Jan 20237:00 amRNSBlock listing six monthly return
28th Dec 20229:05 amRNSSecond Price Monitoring Extn
28th Dec 20229:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.